Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians

Table 1 Biosimilars available in ambulatory care in Belgium (May 2021) [10]

INN	Product type	Net 2019 expenditure [26]	Reference product	Biosimilar	Reimbursement date biosimilar** [27]
Adalimumab*	TNF inhibitor	95.207.248	Humira®	Amgevita®	1/10/2018
				Hulio®	1/1/2019
				Hyrimoz®	1/1/2019
				Idacio®	1/10/2019
				Imraldi®	1/10/2018
Enoxaparin*	LMWH	22.446.229	Clexane®	Ghemaxan®	1/1/2021
Etanercept*	TNF inhibitor	45.197.777	Enbrel®	Benepali®	1/09/2016
				Erelzi®	1/7/2019
				Nepexto®	1/2/2021
Filgrastim	G-CSF	NPA	Neupogen®	Accofil®	1/6/2016
				Nivestim®	1/3/2014
				Tevagrastim®	1/2/2010
Follitropin alfa	FSH	NPA	Gonal-F®	Bemfola®	NA
Follitropin alfa	FSH	NPA	Gonal-F®	Ovaleap®	NA
Insulin glargine*	Long-acting insulin analogue	30.344.794	Lantus®	Abasaglar®	1/6/2016
Somatropin	Growth hormone	NPA	Genotropin®	Omnitrope®	1/4/2014

G-CSF granulocyte colony-stimulating factor, INN international non-proprietary name, LMWH low molecular weight heparin, NPA not publicly available, NA not applicable, non-reimbursed medicines, FSH follicle-stimulating hormone, TNF tumor necrosis factor
^*Biologicals that are part of the top 25 medicine expenditures in the Belgian ambulatory sector. Insulin aspart is also part of this list (reference product: NovoRapid®, net 2019 expenditure: 22.229.748) and has an authorized biosimilar: Insulin aspart Sanofi®. Insulin aspart Sanofi® has, however, not (yet) been launched in Belgium [26]. Also the EU-approved biosimilars of teriparatide (reference product: Forsteo®, EU-approved biosimilars: Movymia®, Terrosa®, Livogiva®, Qutavina®) and insulin lispro (reference product: Humalog®, EU-approved biosimilar: Insulin Lispro Sanofi®) are not (yet) available on the market in Belgium [6, 26, 28]
^**Reimbursement date of the first available product package

ISSN: 2052-3211